Chronic kidney disease occurs when the kidneys are damaged
and unable to filter blood appropriately. It is difficult to regenerate or
recover kidney function once it has been compromised. This can result in
nephrolithiasis and renal failure. This study aims to discover MSC therapy’s
effectiveness in treating Renal failure and Nephrolithiasis. Mesenchymal stem
cells (MSCs) are the prime candidates for regenerative medicine and cell
therapy. MSCs can be obtained and isolated from a variety of tissues such as the
umbilical cord, the placenta, amniotic fluid, adipose tissue, etc. This case
report describes a 58-year-old male with a history of recurrent
nephrolithiasis, decreased estimated glomerular filtration rate (eGFR),
elevated blood urea nitrogen (BUN), and elevated serum creatinine with a
concern for chronic kidney disease (CKD), stage 3 development who was treated
with a total of four MSCs treatments of 5.0 × 108 MSCs per infusion over the
course of two months. Post-treatment five years later revealed no recurrent
nephrolithiasis and normal eGFR, serum BUN, and creatinine levels which suggest
that MSCs can be a safe and effective modern treatment for CKD and
nephrolithiasis. Early diagnosis and treatment with MSC therapy have the
potential to improve renal failure and could be the gold standard to prevent
future hemodialysis or kidney transplantation.
Author(s) Details:
Sebo Gene Wang,
American Stem Cell Base, California, USA.
Sebo
Michelle Wang,
Loma
Linda University School of Medicine, California, USA.
Ming Chu Hsu,
American Stem Cell Base, California, USA.
Fu Nan Wang,
American Stem Cell Base, California, USA.
Please see the link here: https://stm.bookpi.org/RUDHR-V4/article/view/13753
No comments:
Post a Comment